Perseid Therapeutics to co-develop and commercialize next-generation CTLA4-Ig therapeutics

Download PDF Copy

Jan 19 2010

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics. Perseid has received a $5 million payment from Astellas for achievement of this milestone.

“This milestone represents important progress in our next-generation CTLA-4 program”

“This milestone represents important progress in our next-generation CTLA-4 program,” said Grant Yonehiro, CEO of Perseid. “It exemplifies the outstanding work that has been accomplished by the Perseid-Astellas team. We are pleased to have such a strong collaboration with such an exceptional global partner.”

Source:

Maxygen, Inc.

Posted in: Medical Science News

Comments (0)

Download PDF Copy

Suggested Reading

Fluidic Sciences acquires business and assets of Sphere Bio to accelerate single-cell and protein interaction discovery

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do

Clinical trial finds pork meals enhance recovery and mood in military cadets

Hemp seeds: The surprisingly complete protein hiding in plain sight

Eating more animal protein may slightly lower cancer mortality

High protein diet linked to increased risk of cancer-associated venous thromboembolism

UNSW researchers identify key protein that regulates fat storage in cells

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.